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SUMMARY. A sensitive and accurate HPLC-UV method for the quantiﬁcation of ﬂuconazole (FNZ) in hu-
man plasma has been developed. The sample was prepared by liquid–liquid extraction (LLE) of FNZ from
plasma using ethyl acetate. Nevirapine (NVP) was used as internal standard. The chromatographic reten-
tion times of FNZ and NVP were 3.4 and 5.7 min, respectively. The lower limit of quantitation (LLOQ)
was 0.5 μg/mL, and no interferences were detected in the chromatograms. The HPLC-UV method was val-
idated by evaluating its intra-day and inter-day precisions and accuracies in a linear concentration range
between 0.5 and 8.0 μg/mL. The method was developed, validated and successfully applied to bioequiva-
lence studies involving the oral administration of a single 150 mg FNZ capsules in healthy Brazilian male
volunteers.
